← Every company
Amgen Inc Patents
What Amgen Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
AMGN on carbonthat →Filings on file
61
Granted
0
Still pending
61
Filed under
3 names
61 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| APELIN POLYPEPTIDESC07K 7/08, C07K 14/47, A61K 47/542, A61K 47/60, A61P 9/00, A61P 9/12, A61P 9/04, A61K 38/00, A61K 38/10, C07K2319/30Filed as AMGEN INC.2026-06-04Jerry Ryan HOLDER | pending |
| SYSTEMS FOR PERFORMING CELLULAR ANALYSIS AND RELATED DEVICES FOR CONDITIONING ENVIRONMENTS ADJACENT CHIPS IN SUCH SYSTEMSB01L 5/00, B01L 9/527, B01L 7/00, B01L2200/026, B01L2200/0684, B01L2200/14, B01L2300/048, B01L2300/0609, B01L2300/0654, B01L2300/0663, B01L2300/0816, B01L2300/10, B01L2300/1838, B01L2300/1894, G01N 21/0332, G01N2021/151, G01N2021/158, G02B 21/28, G02B 21/30Filed as AMGEN INC.2026-05-07Craig Michael SCHULZ | pending |
| IL-10 MUTEINS AND FUSION PROTEINS THEREOFC07K 14/5428, A61P 29/00, A61K 38/00, A61K2039/505, C07K 16/2803, C07K2317/21, C07K2317/30, C07K2317/33, C07K2317/52, C07K2317/55, C07K2317/56, C07K2317/60, C07K2317/76, C07K2317/92, C07K2317/94, C07K2319/00Filed as AMGEN INC.2026-04-15Hailing HSU | pending |
| SYNTHESIS OF VINYL CYCLOBUTYL INTERMEDIATESC07C 67/14, C07C 67/62, C07D 249/18, Y02P 20/55, C07C2601/04, C07B2200/13, C07C 69/76, C07C 303/26, C07C 309/23, C07C 309/72, C07D 513/08, C07D 513/10, C07D 519/00Filed as AMGEN INC.2026-04-13Austin G. SMITH | pending |
| COMBINATION OF LILRB1/2 PATHWAY INHIBITORS AND PD-1 PATHWAY INHIBITORSC07K 16/2803, C07K 16/2818, A61P 35/00, A61K2039/507, C07K 16/2827, C07K 16/2833, C07K2317/34, C07K2317/565, C07K2317/73, C07K2317/76, C07K2317/92Filed as AMGEN INC.2026-04-09Xin YU | pending |
| MAGNETIC ASSISTED SEPARATION APPARATUSES AND RELATED METHODSB03C 1/08, B03C 1/288, B01L 9/06, B01L2200/023, B01L2200/0668, B03C 1/01, B03C 1/0332, B03C 1/30, B03C2201/18, B03C2201/26, G01N 1/34, G01N 35/0098, G01N 35/1065Filed as AMGEN INC.2026-04-08Craig Michael Schulz | pending |
| MCL-1 Inhibitor FormulationsA61K 9/0053, C07D 519/00, A61P 35/02, A61P 35/00, A61K 9/146, A61K 9/20, A61K 31/553, C07B2200/13Filed as AMGEN INC.2026-04-06James E. HUCKLE | pending |
| DRUG DELIVERY DEVICE AND METHODS OF DELIVERING A DRUGA61M 5/2033, A61M 5/31536, A61M 5/3158, A61M 5/281, A61M 5/31501, A61M 5/31535, A61M 5/3157, A61M 5/31581, A61M 5/31591, A61M 5/3204, A61M 5/3243, A61M 5/326, A61M2005/2013, A61M2005/2026, A61M2005/208, A61M2005/3247, A61M2005/3267, A61M2205/581, A61M2205/582Filed as AMGEN INC.2026-04-03Emil Finkelstein | pending |
| DRUG DELIVERY DEVICE, SUBASSEMBLY FOR DRUG DELIVERY DEVICE, SYRINGE HOLDER, AND METHOD OF ASSEMBLYA61M 5/2033, A61M 5/3204, A61M2005/2013, A61M2005/2437, A61M2005/3247, A61M2005/3267, A61M2207/00Filed as AMGEN INC.2026-04-03Lars Eilertsen | pending |
| DRUG DELIVERY DEVICEFiled as AMGEN INC.2026-03-25BJARKE LYKKE LUDVIG SVENDSEN | pending |
| DRUG DELIVERY DEVICEA61M 5/2033, A61M 5/206, A61M 5/31578, A61M 5/3213, A61M 5/3245, A61M 5/425, A61M 5/46, A61M2005/2013, A61M2005/208, A61M2005/3254, A61M2005/3267, A61M2202/0007, A61M2210/04Filed as AMGEN INC.2026-03-25Bjarke Lykke Ludvig SVENDSEN | pending |
| USE OF ONCOLYTIC VIRUSES FOR THE TREATMENT OF CANCERC12N 7/00, C12N 15/86, A61P 35/00, A61K 35/763, A61K 38/179, A61K 38/208, C07K 14/52, C07K 14/5434, C07K 14/71, C07K2319/00, C12N2710/16632, C12N2710/16643, C12N2710/16671, C12N2830/50Filed as AMGEN INC.2026-03-20Jason James DEVOSS | pending |
| COMBINATION THERAPY FOR SMALL CELL LUNG CANCERFiled as AMGEN INC.2026-03-12AMANDA PARKES | pending |
| DRUG DELIVERY DEVICES AND TAMPER-RESISTANT FEATURES FOR DRUG DELIVERY DEVICESFiled as AMGEN INC.2026-03-12CALVIN CLARK | pending |
| Formulations Of ApremilastA61K 9/2009, A61K 9/2072, A61K 31/4035, A61P 17/06, A61P 19/02, A61P 1/00, A61P 29/00, A61K 9/0004, A61K 9/0065, A61K 9/2013, A61K 9/2018, A61K 9/2031, A61K 9/2054, A61K 9/2086, A61K 9/2853, A61K 9/2866Filed as AMGEN INC.2026-03-12William Brett Caldwell | pending |
| METHODS AND SYSTEMS FOR PREDICTING PHARMACEUTICAL MATERIAL STABILITYFiled as AMGEN INC.2026-03-11TRAVIS WOLTER | pending |
| THE USE OF LOW MOLECULAR WEIGHT POLYVINYLPYRROLIDONE (PVP) TO REDUCE VISCOSITY OF HIGH CONCENTRATION PROTEIN FORMULATIONSA61K 9/0019, A61K 47/32, A61K 9/19, A61K 38/00, A61K 47/183Filed as AMGEN INC.2026-03-10Christopher James SLOEY | pending |
| AUTOMATED VISUAL INSPECTION IMAGE PROCESSING FOR DETECTING CONTAINER AND PARTICULATE DEFECTSFiled as AMGEN INC.2026-03-09JONATHAN A. MALAVE AGOSTO | pending |
| Systems and Methods for Automated In-Line Plunger Depth MeasurementG01B 11/14, G06T 7/001, G06T 7/11, G16H 40/40, G16H 40/63, A61M 5/31565, A61M2205/3306, G01B 11/22, G01B2210/50, G01F 11/027, G06T2207/30004Filed as AMGEN INC.2026-03-06Al Patrick Goodwin | pending |
| DATA-DRIVEN PREDICTIVE MODELING FOR CELL LINE SELECTION IN BIOPHARMACEUTICAL PRODUCTIONC12M 47/04, G16B 40/00, G01N 15/1433, C12M 41/48, G01N2015/1006, G01N2015/1486Filed as AMGEN INC.2026-03-05Kim H. Le | pending |
| 4-1BB+FAP BINDING CONSTRUCTSFiled as AMGEN INC.2026-02-27MATTHEW CHUN | pending |
| COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERSA61K 31/519, A61K 45/06, C07K 16/2818, A61P 35/00, A61K 31/444, A61K 31/506, A61K 31/555, A61K 39/3955, A61K 39/39558, A61K 39/39566, A61K2300/00Filed as Amgen Inc.2026-02-26James Russell LIPFORD | pending |
| DRUG DELIVERY DEVICEFiled as AMGEN INC.2026-02-24ANDERS ELMER JENSEN | pending |
| SYSTEMS FOR USE DURING EXTERNAL STERILIZATION OF DRUG DELIVERY DEVICESFiled as AMGEN INC.2026-02-18NICHOLAS ANDREW DESANTIS | pending |
| DRUG DELIVERY DEVICEFiled as AMGEN INC.2026-02-13ANDERS ELMER JENSEN | pending |
| HYBRID PREDICTIVE MODELING FOR CONTROL OF CELL CULTUREC12M 41/46, C12M 41/48, G06N 20/10, G06N 3/09, G06N 3/0464, C12M 29/00, C12M 41/32, C12M 41/44, G01J 3/28, G01J 3/44, G01N 21/65, G06N 3/084Filed as AMGEN INC.2026-02-12Mohammad Rashedi | pending |
| FORMULATIONS OF (+)-2-[1-(3-ETHOXY-4- METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONEA61K 9/2013, A61K 9/284, A61P 27/02, A61P 17/06, A61P 19/06, A61P 17/00, A61P 19/02, A61P 29/00, A61P 1/04, A61K 9/2018, A61K 9/2054, A61K 9/2813, A61K 9/2826, A61K 9/2853, A61K 9/2866, A61K 31/4035Filed as Amgen Inc.2026-02-10Sreenivas S. Bhat | pending |
| SYSTEMS AND METHODS FOR VISUAL ANOMALY DETECTIONFiled as AMGEN INC.2026-02-05IAN HULLEY | pending |
| COMPOUNDS AS MODULATORS OF IGF-1R AND USES THEREOFFiled as AMGEN INC.2026-01-14ASHLEY FENWICK | pending |
| HETEROCYCLIC INHIBITORS OF IGF-1R AND USES THEREOFA61K 31/437, C07D 471/04, A61P 35/00, A61K 31/4439, C07D 401/06, C07D 401/12, C07D 401/14, C07D 405/14, C07D 409/14Filed as AMGEN INC.2026-01-12Ashley FENWICK | pending |
| AUTOMATED GRADIENT PATCH CELL PLATINGFiled as AMGEN INC.2026-01-12SARAH VAN DRIESCHE | pending |
| HETEROCYCLIC INHIBITORS OF IGF-1R AND USES THEREOFFiled as AMGEN INC.2026-01-12ASHLEY FENWICK | pending |
| OPTIC LABELS FOR DRUG STORAGE CONTAINERSFiled as AMGEN INC.2026-01-09KAY DIEHNELT | pending |
| SYSTEMS AND METHODS FOR INSPECTING PRODUCTS ON A PRODUCTION LINEFiled as AMGEN INC.2026-01-09MARTIN VAN WEZEL | pending |
| SYSTEMS AND METHODS FOR PACKAGING PHARMACEUTICAL ARTICLESFiled as AMGEN INC.2026-01-06MARTIN VAN WEZEL | pending |
| CONVERGENT PEPTIDE SYNTHESIS METHODSFiled as AMGEN INC.2025-12-29JAMES MURRAY | pending |
| CONVERGENT PEPTIDE SYNTHESIS METHODSC07K 1/10, C07K 14/605, A61P 3/04, A61P 3/10, A61K 38/00, C07K 1/02, C07K 1/04, C07K2319/00Filed as AMGEN INC.2025-12-29James Murray | pending |
| COMBINATION THERAPY FOR SMALL CELL LUNG CANCERFiled as AMGEN INC.2025-12-22Amanda PARKES | pending |
| METHODS OF DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA) QUANTIFICATIONFiled as AMGEN INC.2025-12-19CHRISTINA JOY WELCH-FORD | pending |
| METHODS AND SYSTEMS FOR DETERMINING AN IMPACT OF ATTRIBUTESG16H 20/10Filed as AMGEN INC.2025-12-19SIDDHARTH PRABHU | pending |
| T CELL ENGAGER MASKING MOLECULES WITH REDUCED ISOMERIZATION TENDENCIESFiled as AMGEN INC.2025-12-19TIM ACKER | pending |
| CHARGE PAIR MUTATIONS TO ENABLE CORRECT HEAVY-LIGHT CHAIN PAIRINGC07K 16/00, C07K2317/31, C07K2317/522, C07K2317/524, C07K2317/526, C07K2317/565Filed as Amgen Inc.2025-12-19Timothy Patrick RILEY | pending |
| PRODUCT QUALITY ATTRIBUTE TARGET RANGESG06Q 30/018, G16H 50/70, G16H 70/40, G16H 10/20Filed as AMGEN INC.2025-12-18Siddharth PRABHU | pending |
| DRUG DELIVERY DEVICES AND FLANGE EXTENSION MEMBERSFiled as AMGEN INC.2025-12-17JUSTIN BERELSMAN | pending |
| Systems and Methods for Assessing Cell Growth RatesG06T 7/0016, G06T2207/20084, G06T2207/30024Filed as AMGEN INC.2025-12-17Yu Yuan | pending |
| CONTROL OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTUREC07K 16/00, C12N 15/1138, C07K 16/28, C07K2317/41, C12P 21/005Filed as AMGEN INC.2025-12-16Chung-Jr HUANG | pending |
| COMPOUNDS AS MODULATORS OF STAT6 AND USES THEREOFA61K 31/5377, C07D 401/10, A61P 37/00, A61K 31/402, A61K 31/404, A61K 31/4178, A61K 31/4192, A61K 31/4196, A61K 31/422, A61K 31/423, A61K 31/4245, A61K 31/427, A61K 31/437, A61K 31/438, A61K 31/4433, A61K 31/4439, A61K 31/444, A61K 31/454, A61K 31/4545, A61K 31/4709, A61K 31/496, A61K 31/4985, A61K 31/501, A61K 31/5025, A61K 31/506, A61K 31/513, A61K 31/517, A61K 31/5355, A61K 31/5383, A61K 31/5386, C07B 59/002, C07D 207/263, C07D 207/27, C07D 213/81, C07D 249/06, C07D 249/12, C07D 401/12, C07D 401/14, C07D 403/10, C07D 403/12, C07D 405/04, C07D 405/10, C07D 405/14, C07D 413/10, C07D 413/14, C07D 417/10, C07D 417/14, C07D 471/04, C07D 471/08, C07D 487/04, C07D 491/048, C07D 495/04, C07D 498/04, C07D 498/10, C07D 519/00Filed as AMGEN INC.2025-12-16Liping H. PETTUS | pending |
| MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORSA61P 35/00, C07K 16/2878, A61P 35/04, A61K2039/505, A61K2039/507, C07K 16/28, C07K 16/30, C07K 16/3076, C07K2317/31, C07K2317/33, C07K2317/35, C07K2317/52, C07K2317/522, C07K2317/524, C07K2317/526, C07K2317/53, C07K2317/55, C07K2317/56, C07K2317/565, C07K2317/567, C07K2317/60, C07K2317/622, C07K2317/64, C07K2317/73, C07K2317/75, C07K2317/92, C07K2319/00Filed as AMGEN INC.2025-12-16Xin YU | pending |
| COMPOUNDS AS MODULATORS OF STAT6 AND USES THEREOFFiled as AMGEN INC.2025-12-16LIPING H. PETTUS | pending |
| LYMPHOTOXIN BETA RECEPTOR AGONIST BINDING PROTEINSC07K 16/2878, A61P 35/00, A61K2039/505, C07K2317/31Filed as AMGEN INC.2025-12-10Rajkumar NOUBADE | pending |
| Processes for Preparing a MDM2 InhibitorC07D 211/76, C07D 263/14, A61P 35/00, H04W 76/38, A61K 31/45, A61K 31/451, C07B2200/13, C07D 263/12, C07D 498/04, H04W 24/02, H04W 48/02, H04W 48/04, H04W 48/06, H04W 48/08, H04W 48/10, H04W 48/12, H04W 48/14, H04W 48/16, H04W 60/00Filed as Amgen, Inc.2025-12-09Sebastien Caille | pending |
| LOAD VESSEL DRAINING SYSTEM AND METHODFiled as AMGEN INC.2025-12-09BRET E. WYLIE | pending |
| NEXT-GENERATION SEQUENCING PLATFORM FOR SEQUENCE VARIANT ANALYSIS OF MANUFACTURING CELL LINESFiled as AMGEN INC.2025-12-04JASMINE TAT | pending |
| BIOLOGICAL DETECTION SYSTEMS AND METHODS FOR SETTING MEDICALLY SUITABLE TARGET RANGES OF ATTRIBUTES USING PRINCIPAL COMPONENT ANALYSIS (PCA)Filed as AMGEN INC.2025-12-04ROBERT ANTHONY MERLO | pending |
| T Cell Engager Masking MoleculesC07K 7/08, C07K 16/2803, A61K 47/60, A61P 37/06, A61P 35/02, A61K 38/00, A61K 39/395, A61K2039/505, A61K2300/00, C07K 7/06, C07K 14/7051, C07K 16/2809, C07K 16/2887, C07K 16/3069, C07K2317/31, C07K2317/34, C07K2317/524, C07K2317/526, C07K2317/53, C07K2317/55, C07K2317/565, C07K2317/622, C07K2317/92, C07K2319/31, C07K2319/70Filed as AMGEN INC.2025-12-03Kip Conner | pending |
| BISPECIFIC LYMPHOTOXIN BETA RECEPTOR BINDING PROTEINSFiled as AMGEN INC.2025-11-28NATHAN WILLIAM PIERCE | pending |
| TITRATION DOSES OF MARIDEBART CAFRAGLUTIDEFiled as AMGEN INC.2025-11-26SIDDIQUE A. ABBASI | pending |
| COMPOSITIONS COMPRISING SOTORASIBA61K 31/519, A61K 9/2013, A61K 9/2018, A61K 9/2027, A61K 9/2054, A61K 47/32, A61K 47/38Filed as AMGEN INC.2025-11-25Fernando Antonio ALVAREZ-NUNEZ | pending |
| DRIVE ASSEMBLY FOR A DRUG DELIVERY DEVICE AND RELATED METHODSFiled as AMGEN INC.2025-11-25JAN MIKAEL JENSEN | pending |
| DRIVE ASSEMBLY FOR A DRUG DELIVERY DEVICE AND RELATED METHODSA61M 5/2033, A61M 5/31501, A61M 5/31578, A61M2005/202, A61M2005/2026, A61M2005/2073, A61M2005/208, A61M2005/31508, A61M2005/3151, A61M2202/0007, A61M2202/04, A61M2205/8281, A61M2207/10Filed as AMGEN INC.2025-11-25Jan Mikael JENSEN | pending |
| 6-MEMBERED RING SYSTEM COMPOUNDS AS DEGRADERS OF MSH3Filed as AMGEN INC.2025-11-25Kate ASHTON | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on AMGN
Company overviewEverything on AMGN in one place, with the price.SEC filingsWhat AMGN's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat AMGN's own officers and directors buy and sell.Executive payWhat AMGN awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in AMGN.Funds holding itWhich funds and ETFs hold AMGN, and how big a bet.LobbyingWhat AMGN spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on AMGN's account, and who they worked for.Federal contractsWhat federal agencies pay AMGN.